Bayer plans to build a state-of-the-art site in New Albany, Ohio, USA, to serve local patients as well as globally.
Bayer expects to create around 600 new high-value jobs in the area.
The multi-year investment reinforces it US business expansion and adds to more than US $7 billion in US pharma R&D and manufacturing expenditure over past five years.
The flexible, modular campus is designed to combine drug substance and drug product manufacturing, leverage advanced digital and automation technologies, and support our growing portfolio initially in oncology, cardiovascular and renal care. The first module, dedicated to drug substance manufacturing, is expected to become operational in 2031.
A second module for drug product manufacturing is planned to follow in 2034. The new site will complement Bayer’s US pharmaceuticals headquarters in Whippany, New Jersey and its other sites in Pittsburgh, Pennsylvania; Berkeley, California; Cambridge, Massachusetts; Research Triangle Park, North Carolina; and San Diego, California, USA.
